SANTA BARBARA, Calif., Jan. 28, 2015 – VG Life Sciences, (VGLS), a biotechnology company developing therapies for autoimmune and infectious diseases, today announced the U.S. Patent and Trademark Office (USPTO) has issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD) through the administration of a CLIP-inducing agent.

The patent, along with the company’s existing intellectual property, demonstrates VG Life Sciences’ expertise in researching the role of CLIP (class II-associated invariant chain peptide) in chronic inflammatory conditions.

The company’s research hypothesizes that when an epithelial or endothelial cell of the mucosal tract is devoid of the cell’s own CLIP, the cell will be susceptible to mediated cell death causing the autoimmune condition.

The invention is based in part on the company-sponsored discovery that CLIP provides a protective armor on a cell surface, shielding it from mediated cell death that occurs in certain diseases. Therefore agents that promote CLIP, including exogenous CLIP, are useful in the treatment of mucosal system disorders and autoimmune diseases, especially ulcerative colitis.

“This patent fortifies our growing intellectual property portfolio in the field of autoimmune diseases and further validates the company’s expertise in elucidating the complicated yet important role CLIP plays in many chronic inflammatory and autoimmune conditions,” said David Odell, VG Life Sciences’ CFO. “Current therapies for IBD treat the symptoms but don’t address the underlying immune response. As one of the more than 1.3 million people in the U.S. who have suffered with IBD, I’m very excited by the potential of the company’s research to address this unmet need.”

VG Life Sciences plans to continue its research in this area with the goal of taking it through pre-clinical studies.

About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. VGLS controls over 40 U.S. and international patents and pending patents protecting its exclusive biotech platform technologies. For more information and upcoming events, visit or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Forward-Looking Statements
This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences’ drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world.

Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, FOR IMMEDIATE RELEASE 2 Visit the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact: Media – Terri Somers
Somers Media

SOURCE VG Life Sciences Inc.


Author VGLS     Tags None